**Impacts of Lowered CLSI Breakpoints on Reported Susceptibility Levels of Imipenem and Meropenem in the TEST Program**

R. Badal1, S. Bouchillon1, B. Johnson1, M. Hackel1, M. Dowzicky2
1International Health Management Associates, Inc., Schaumburg, IL USA
2Pfizer Inc., Collegeville, PA USA

**Revised Abstract**

**Background:** In June 2010, CLSI lowered carbapenem susceptibility breakpoints for Enterobacteriaceae. These changes will reduce reported susceptibility levels for these agents, and thus it is important to the laboratories and laboratories should be prepared to explain the changes in susceptibility percentages that may be reported for these agents when the new breakpoints are published. The Tigecycline Evaluation Surveillance Trial (TEST) has been monitoring susceptibility levels of ticarcillin and other drugs since 2004. This report evaluates the impact of the new carbapenem breakpoints on reported susceptibility of imipenem (Imp) and meropenem (Mer) in the TEST program.

**Methods:** 25,458 and 53,986 isolates of Enterobacteriaceae were collected and tested vs. Imp and Mer, respectively, from 2004-2009 using broth microdilution following CLSI guidelines. Susceptibility to Imp and Mer was calculated using 2009 and 2010 CLSI breakpoints. **Results:** Imp and Mer %S/I/R values using 2009 and 2010 CLSI breakpoints are shown below for all Enteroabacteriaceae.

**Introduction**

The clinical and laboratories standards institute (CLSI) establishes susceptibility testing interpretive standards for antimicrobial agents. In the United States, the Food and Drug Administration (FDA) also establishes interpretive breakpoints for all new antimicrobics; however, the FDA does not have a well-established mechanism to routinely review its breakpoints to ensure that they accurately reflect the current body of knowledge about resistance mechanisms found in pathogens. The CLSI, on the other hand, can and does review the performance of its breakpoints periodically, and when new mechanisms of resistance are reported that were unrecognized when a drug was originally introduced for clinical use, the susceptibility breakpoints need to be revised to ensure they accurately identify isolates with a high probability of treatment failure. Furthermore, as the science of pharmacokinetics/pharmacodynamics (PK/PD) has advanced over the past several years, it has been applied more and more by CLSI and other bodies such as the FDA and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) to identify more appropriate susceptibility breakpoints.

The advert and spread in bacteria of carbapenemases hydrolyzing one or more carbapenems (imipenem, meropenem, ertapenem, doripenem) and the application of PK/PD information led the CLSI (and EUCAST) to propose new breakpoints (M100-S20-U) for these agents, and to select similar breakpoints for the more recently launched doripenem. However, changes of such magnitude will take a few years to be fully implemented by the manufactures of antimicrobial susceptibility testing (AST) systems (bioMerieux Vitek, Siemens MicroScan, BD Phoenix, Trek Sensititre, etc.). As laboratories implement the new breakpoints either independently or when their AST provider releases new testing devices and software incorporating the new breakpoints, there will be a "sudden" increase in resistant or non-susceptible isolates to these carbapenems, almost entirely due to the lower breakpoints. This report shows the magnitude of change that most labs can expect to see, and can serve to help prepare laboratories and hospitals to explain the changes to their physicians, and differentiate between changes due to lower breakpoints and those due to a genuine increase in prevalence of carbapenemase-producing isolates.

**Materials and Methods**

- All isolates were derived from blood, respiratory tract, urine (no more than 25% of all isolates), skin, wound, body fluids, and other defined sources. Only one isolate per patient was accepted into the study.
- Clinical isolates were collected and tested between 2004 and 2009 from 1,509 cumulative investigative sites in 59 countries globally. Isolates were identified to the species level and tested at each site by the participating laboratory.
- Organism collection, transport, confirmation of organism identification, and development and management of a centralized database, were coordinated by Laboratories International for Microbiology Studies (LIMS), a division of International Health Management Associates, Inc. located in Schaumburg, IL, USA.
- Minimum inhibitory concentrations (MICs) for imipenem and meropenem were determined by the Clinical and Laboratory Standards Institute (CLSI) recommended broth microdilution testing method (M100-S20-U).
- Quality controls (QC) were performed by each testing site on each day of testing using the CLSI-recommended ATCC control strains: Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853. Results were included in the analysis only when corresponding QC isolates tested within the acceptable range according to CLSI 2010 guidelines [2].

**Results**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Breakpoints (S/I/R)</th>
<th>% Susceptible</th>
<th>% Intermediate</th>
<th>% Resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imp</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>25,458</td>
</tr>
<tr>
<td>Imp</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>25,458</td>
</tr>
<tr>
<td>Mer</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>53,986</td>
</tr>
<tr>
<td>Mer</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>53,986</td>
</tr>
</tbody>
</table>

**Conclusions**

- Although the lower carbapenem breakpoints published in CLSI M100-S20-U in June 2010 only cause a drop in Enterobacteriaceae susceptibility percentages of 2.51% and 1.66% for imipenem and meropenem, respectively, the proportional increase in percentages reported as intermediate and resistant appear much larger due to their very small starting points.
- One other than South Pacific, most regions of the world will see their carbapenem resistance rates "significantly" increase upon implementation of the M100-S20-U breakpoints; however, the reported increases will be due almost entirely to the lowered breakpoints, not a genuine increase in rates compared to previous years.
- The advent and spread in bacteria of carbapenemases hydrolyzing one or more carbapenems (imipenem, meropenem, ertapenem, doripenem) and the application of PK/PD information led the CLSI (and EUCAST) to propose new breakpoints for these agents, and to select similar breakpoints for the more recently launched doripenem. However, changes of such magnitude will take a few years to be fully implemented by the manufactures of antimicrobial susceptibility testing (AST) systems (bioMerieux Vitek, Siemens MicroScan, BD Phoenix, Trek Sensititre, etc.). As laboratories implement the new breakpoints either independently or when their AST provider releases new testing devices and software incorporating the new breakpoints, there will be a "sudden" increase in resistant or non-susceptible isolates to these carbapenems, almost entirely due to the lower breakpoints. This report shows the magnitude of change that most labs can expect to see, and can serve to help prepare laboratories and hospitals to explain the changes to their physicians, and differentiate between changes due to lower breakpoints and those due to a genuine increase in prevalence of carbapenemase-producing isolates.

**References**